Last reviewed · How we verify
generic sevoflurane
Sevoflurane is a volatile anesthetic that enhances inhibitory neurotransmission and suppresses excitatory neurotransmission in the central nervous system to produce unconsciousness and anesthesia.
Sevoflurane is a volatile anesthetic that enhances inhibitory neurotransmission and suppresses excitatory neurotransmission in the central nervous system to produce unconsciousness and anesthesia. Used for Induction and maintenance of general anesthesia in adults and pediatric patients undergoing surgery, Sedation in intensive care settings.
At a glance
| Generic name | generic sevoflurane |
|---|---|
| Also known as | Sevofran® (Hana Pharmacy, Co. Ltd, Seoul, Korea) |
| Sponsor | Asan Medical Center |
| Drug class | Volatile halogenated ether anesthetic |
| Target | GABA-A receptor, NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Sevoflurane acts primarily as a positive allosteric modulator of GABA-A receptors and an antagonist of NMDA receptors, leading to depression of the central nervous system. It produces rapid induction and emergence from anesthesia with minimal airway irritation, making it suitable for both inhalational induction and maintenance of general anesthesia across diverse surgical and procedural settings.
Approved indications
- Induction and maintenance of general anesthesia in adults and pediatric patients undergoing surgery
- Sedation in intensive care settings
Common side effects
- Postoperative nausea and vomiting
- Emergence agitation
- Airway irritation
- Hypotension
- Bradycardia
Key clinical trials
- The Effect of General Anesthesia on the Middle Ear Pressure (NA)
- Two Different Preparations of Sevoflurane in Induction (PHASE4)
- Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- generic sevoflurane CI brief — competitive landscape report
- generic sevoflurane updates RSS · CI watch RSS
- Asan Medical Center portfolio CI